Faeth Therapeutics, Inc.
FTH Nasdaq
SEC CIK 1829802
Follow Faeth Therapeutics
Weekly email: filings, results
Net income
−$20.4M
−346.4% vs same quarter last year
EPS, diluted
−$0.79
+78.2% vs same quarter last year
Operating cash flow
−$13M
−262.6% vs same quarter last year
Operating income
−$22.1M
−355.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$21.1M |
| FY24 | −$30.2M |
| FY23 | −$34.1M |
| FY22 | −$48.6M |
| FY21 | −$36.8M |
| FY20 | −$20.1M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$20.5M |
| FY24 | −$24.8M |
| FY23 | −$32.2M |
| FY22 | −$39.3M |
| FY21 | −$32.3M |
| FY20 | −$18.9M |
| FY19 | - |